◆英語タイトル:MarketVIEW: RSV vaccines - Vaccine opportunity assessment
◆発行会社(調査会社):VacZine Analytics
◆レポート形式:PDF, Excel
Executive Presentation (PDF)GBP3,500 ⇒換算¥497,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,500 ⇒換算¥497,000見積依頼/購入/質問フォーム
PDF+ExcelGBP7,000 ⇒換算¥994,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

Respiratory syncytial virus (RSV) is a leading cause of acute infant/childhood (< 5yrs) lower respiratory tract infections (ALRIs) and hospitalization. In particular, elderly adults and/or those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. On a global basis, RSV is estimated to be responsible for 30 million episodes and 53,000 to 199,000 deaths per year, mostly children. 99% of deaths occur in developing countries.

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in “at risk” groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is from US biotech Novavax (RSV-F) who have recently entered Phase III trials with a VLP recombinant fusion protein. An adult filing is expected in 1H 2017.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets1 to 2035. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups (maternal, elderly and “at risk”). Differing RSV vaccine profiles (infant + maternal + elderly) and related issues such as differential pricing are also discussed along with an up-to-date review of epidemiology and the competitive environment, R&D pipeline.




****This product is composed of a model and summary presentation

Executive summary
Authors note
Executive summary
RSV vaccines: Commercial model – key outputs
Predicted global sales ($m) by target segment, 2015-2035
Predicted infant and maternal immunization sales ($m), 2015-2035
Predicted infant immunization sales ($m) by country/region, 2030
Predicted maternal immunization sales ($m) by country/region, 2030
Predicted elderly and at-risk immunizations sales ($m), 2015-2035
Predicted elderly immunization sales ($m), by country/region, 2030
Predicted “at-risk” immunization sales ($m), by country/region, 2030
Predicted global volume per segment (doses) to 2035
RSV vaccines: Commercial model – key assumptions
The role of RSV vaccines
RSV vaccine target populations: overview
RSV vaccine: infant target product profile (TPP)
RSV vaccine: maternal immunization target product profile (TPP)
RSV vaccine: elderly/at-risk target product profile (TPP)
Markets/regions included in model
RSV vaccine predicted uptake per country/region
Forecast comparisons: March 2016 vs. April 2014*
Pricing: infant and maternal immunization
Pricing: elderly and at-risk immunization
Pricing: elderly and at-risk immunization (cont..)
RSV vaccines: R&D pipeline
Competitor landscape: overview
Novavax: elderly immunization
Novavax: elderly immunization – Phase III
Novavax: elderly immunization – trial review
Novavax: maternal immunization
Novavax: maternal immunization – Phase II results
Novavax: maternal immunization – US seasons
Novavax: maternal immunization – Phase III
Novavax: maternal immunization – trial review
Novavax: infant immunization
GSK: maternal and infant immunization
Other companies with clinical stage RSV vaccines
RSV – review of latest epidemiology
Epidemiology: overview (3 slides)
RSV disease burden: infants
RSV disease burden: US infants
RSV disease burden: infants – hospitalizations
RSV disease burden: infants – bronchiolitis
RSV disease burden: infants – lower income countries
RSV disease burden: infants – India
RSV disease burden: infants – vaccine strategy
RSV disease burden: elderly (8 slides)
RSV disease burden: elderly – Cardiopulmonary disease
Back-up material
Methodology – populations
Methodology – vaccine uptake (14 slides)
About VacZine Analytics